{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:52:20Z","timestamp":1759092740771},"reference-count":19,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Prolonged QT interval (QTc) can be a serious adverse event from SARS-CoV-2 infection and associated treatment, including remdesivir. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> We present a case of a 55-year-old woman with COVID-19 pneumonia who was treated with remdesivir. The QTc on admission was 483 ms. After three doses of remdesivir, she had an episode of non-sustained ventricular tachycardia. Repeat QTc was significantly prolonged at 609 ms. She experienced a polymorphic ventricular tachycardic cardiac arrest the next morning, thought to be secondary to torsades de pointes. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Transthoracic echocardiogram showed normal biventricular function. Electrolytes were within normal limits. In the absence of other QTc-prolonging medications, remdesivir was thought to be inciting agent. Following discontinuation of remdesivir, the patient's QTc returned to baseline. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> There is a risk for cardiac events from QTc prolongation effects of SARS-CoV-2 infection and associated treatment. We recommend pharmacological profile review and cardiac monitoring for patients receiving remdesivir. <\/jats:p><\/jats:sec>","DOI":"10.3138\/jammi-2022-0010","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T16:00:13Z","timestamp":1666800013000},"page":"99-104","source":"Crossref","is-referenced-by-count":2,"title":["Torsades de pointes associated with remdesivir treatment for COVID-19 pneumonia"],"prefix":"10.3138","volume":"8","author":[{"given":"Jollee ST","family":"Fung","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Northern Ontario School of Medicine University, Sudbury, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Levitan","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Department of Anesthesiology, Northern Ontario School of Medicine University, Sault Ste. Marie, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Landry","sequence":"additional","affiliation":[{"name":"Clinical Preceptor, University of Waterloo School of Pharmacy, Waterloo, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"McIsaac","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Department of Critical Care Medicine, Health Sciences North, Sudbury, Ontario, Canada"},{"name":"Division of Clinical Sciences, Department of Anesthesia, Northern Ontario School of Medicine University, Division of Clinical Sciences, Section of Anesthesia, Sudbury, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1696","reference":[{"issue":"10","key":"r1","first-page":"e11132","volume":"12","author":"Gupta AK","year":"2020","journal-title":"Cureus"},{"issue":"19","key":"r2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"Beigel JH","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"r3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"r4","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","volume":"194","year":"2022","journal-title":"CMAJ"},{"key":"r5","unstructured":"Ontario COVID-19 Science Advisory Table. Clinical practice guideline summary: Recommended drugs and biologics in adult patients with COVID-19. Science Table. https:\/\/covid19-sciencetable.ca\/sciencebrief\/clinical-practice-guideline-summary-recommended-drugs-and-biologics-in-adult-patients-with-covid-19-version-9-0\/. (Accessed January 22, 2022)."},{"key":"r6","unstructured":"BC Centre for Disease Control. Antimicrobial and immunomodulatory therapy in adult patients with COVID-19. BCCDC. http:\/\/www.bccdc.ca\/health-professionals\/clinical-resources\/covid-19-care\/clinical-care\/treatments. (Accessed January 22, 2022)."},{"key":"r7","unstructured":"Gilead. Prescribing information for Veklury. Gilead. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/covid-19\/veklury\/veklury_pi.pdf. (Accessed January 26, 2022)."},{"issue":"3","key":"r8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12012-021-09703-9","volume":"22","author":"Nabati M","year":"2022","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"r9","doi-asserted-by":"crossref","first-page":"e216842","DOI":"10.1001\/jamanetworkopen.2021.6842","volume":"4","author":"Rubin GA","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"12","key":"r10","doi-asserted-by":"crossref","first-page":"e0208321","DOI":"10.1371\/journal.pone.0208321","volume":"13","author":"Aromolaran AS","year":"2018","journal-title":"PLoS One"},{"issue":"22","key":"r11","first-page":"1717","volume":"38","author":"Lazzerini PE","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"r12","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","volume":"5","author":"Mercuro NJ","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"7","key":"r13","doi-asserted-by":"crossref","first-page":"e14182","DOI":"10.1111\/ijcp.14182","volume":"75","author":"Haghjoo M","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"1","key":"r14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/cts.12882","volume":"14","author":"Michaud V","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"5","key":"r15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s15010-020-01448-x","volume":"48","author":"Durante-Mangoni E","year":"2020","journal-title":"Infection"},{"issue":"3","key":"r16","doi-asserted-by":"crossref","first-page":"e239963","DOI":"10.1136\/bcr-2020-239963","volume":"14","author":"Aslam W","year":"2021","journal-title":"BMJ Case Reports"},{"issue":"9","key":"r17","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.hrthm.2020.05.008","volume":"17","author":"Jankelson L","year":"2020","journal-title":"Heart Rhythm"},{"issue":"2","key":"r18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo CA","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"r19","unstructured":"Evidencio. Naranjo adverse drug reaction probability scale. https:\/\/www.evidencio.com\/models\/show\/661. (Accessed February 16, 2022)."}],"container-title":["Journal of the Association of Medical Microbiology and Infectious Disease Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jammi.utpjournals.press\/doi\/pdf\/10.3138\/jammi-2022-0010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T15:59:14Z","timestamp":1680019154000},"score":1,"resource":{"primary":{"URL":"https:\/\/jammi.utpjournals.press\/doi\/10.3138\/jammi-2022-0010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3,1]]}},"alternative-id":["10.3138\/jammi-2022-0010"],"URL":"https:\/\/doi.org\/10.3138\/jammi-2022-0010","relation":{},"ISSN":["2371-0888"],"issn-type":[{"type":"electronic","value":"2371-0888"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}